Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)
Raltegravir is the preferred INSTI for for treatment of antiretroviral-naïve pregnant women in the US Perinatal Guidelines, alongside Dolutegravir, and for late pregnancy. There are relatively limited information available on its use during early pregnancy, particularly the peri-conception period. The aim of the study is to assess "real-world" maternal, fetal and newborn outcomes following RAL use during pregnancy through pooled analysis of individual patient data from observational studies participating in the European Pregnancy and Paediatric Infections Cohort Collaboration.
Multi-centre EuRopean study of Major Infectious Disease Syndromes - PREPARE PED-MERMAIDS
Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial - Neomero2
100 Clinical Results associated with Fondazione Penta Onlus
0 Patents (Medical) associated with Fondazione Penta Onlus
100 Deals associated with Fondazione Penta Onlus
100 Translational Medicine associated with Fondazione Penta Onlus